Laurus Labs Ltd
NSE:LAURUSLABS

Watchlist Manager
Laurus Labs Ltd Logo
Laurus Labs Ltd
NSE:LAURUSLABS
Watchlist
Price: 1 012.3 INR -0.69% Market Closed
Market Cap: 546.5B INR
Section:
 

Relative Value

The Relative Value of one LAURUSLABS stock under the Base Case scenario is 910.56 INR. Compared to the current market price of 1 012.3 INR, Laurus Labs Ltd is Overvalued by 10%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LAURUSLABS Relative Value
Base Case
910.56 INR
Overvaluation 10%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

8.6
P/S
P/S
Price to Sales
8.6
vs History
1
vs Industry
21
Median 3Y
4.7
Median 5Y
5
Industry
2.6
Forward
8.1
More Details
79.8
P/E
P/E
Price to Earnings
79.8
vs History
33
vs Industry
1
Median 3Y
90
Median 5Y
36.7
Industry
21.6
Forward
74
More Details
33.3
P/OCF
P/OCF
Price to OCF
33.3
vs History
53
vs Industry
3
Median 3Y
32.8
Median 5Y
33.9
Industry
16.5
More Details
3 617.1
P/FCFE
P/FCFE
Price to FCFE
3 617.1
vs History
1
vs Industry
2
Median 3Y
111.3
Median 5Y
111.3
Industry
22.5
More Details
12.2
P/B
P/B
Price to Book Value
12.2
vs History
6
vs Industry
8
Median 3Y
5.9
Median 5Y
7.4
Industry
2.3
More Details
9
EV/S
EV/S
Enterprise Value to Sales
9
vs History
1
vs Industry
21
Median 3Y
4.8
Median 5Y
5.2
Industry
2.9
Forward
8.4
More Details
15.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
15.6
vs History
1
vs Industry
18
Median 3Y
9.6
Median 5Y
9.9
Industry
5.5
More Details
38.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
38.2
vs History
6
vs Industry
9
Median 3Y
31.4
Median 5Y
21.3
Industry
13
Forward
34.6
More Details
54.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
54.9
vs History
28
vs Industry
5
Median 3Y
53.1
Median 5Y
25.7
Industry
16.6
Forward
48.4
More Details
34.8
EV/OCF
EV/OCF
Enterprise Value to OCF
34.8
vs History
50
vs Industry
4
Median 3Y
34.1
Median 5Y
35.2
Industry
15.8
More Details
74.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
74.1
vs History
53
vs Industry
7
Median 3Y
69.6
Median 5Y
76.6
Industry
19.1
More Details
6.8
EV/IC
EV/IC
Enterprise Value to IC
6.8
vs History
6
vs Industry
17
Median 3Y
3.4
Median 5Y
4.2
Industry
1.9
More Details

Multiples Across Competitors

LAURUSLABS Competitors Multiples
Laurus Labs Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Laurus Labs Ltd
NSE:LAURUSLABS
545.9B INR 8.6 79.8 38.2 54.9
US
Eli Lilly and Co
NYSE:LLY
971.9B USD 16.4 52.8 35.5 38
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
509.1B USD 5.5 20.3 16.6 21.5
CH
Roche Holding AG
SIX:ROG
252.3B CHF 4.1 26.8 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
208.5B GBP 4.8 29.7 108 158
CH
Novartis AG
SIX:NOVN
202.4B CHF 4.5 17.7 11.2 14.5
US
Merck & Co Inc
NYSE:MRK
249.5B USD 3.9 13.1 9.3 11.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.7 9.6 11.2
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
147B USD 2.3 15 7.6 10.4
P/E Multiple
Earnings Growth PEG
IN
Laurus Labs Ltd
NSE:LAURUSLABS
Average P/E: 29.9
79.8
50%
1.6
US
Eli Lilly and Co
NYSE:LLY
52.8
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.7
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
13.1
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Laurus Labs Ltd
NSE:LAURUSLABS
Average EV/EBITDA: 402.3
38.2
32%
1.2
US
Eli Lilly and Co
NYSE:LLY
35.5
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.6
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Laurus Labs Ltd
NSE:LAURUSLABS
Average EV/EBIT: 1 715.1
54.9
43%
1.3
US
Eli Lilly and Co
NYSE:LLY
38
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.1
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
1%
11.2
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
8%
1.3

See Also

Summary
LAURUSLABS intrinsic value, competitors valuation, and company profile.
DCF Valuation
LAURUSLABS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LAURUSLABS stock valuation using valuation multiples.
Wall Street Estimates
LAURUSLABS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LAURUSLABS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 302,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.